| Style | Citing Format |
|---|---|
| MLA | Mehdipoor M, et al.. "Ramelteon, As a Melatonin Agonist, Is Expected to Be Effective on Covid-19 Induced Organ Damage: The Hypothetic Role of Nf-Κb Signaling Pathway." Advanced Biomedical Research, vol. 11, no. 1, 2022, pp. 101-. |
| APA | Mehdipoor M, Mirmotahari S, Nouriyani S, Salehirad M, Darbeheshti S, Motaghinejad M (2022). Ramelteon, As a Melatonin Agonist, Is Expected to Be Effective on Covid-19 Induced Organ Damage: The Hypothetic Role of Nf-Κb Signaling Pathway. Advanced Biomedical Research, 11(1), 101-. |
| Chicago | Mehdipoor M, Mirmotahari S, Nouriyani S, Salehirad M, Darbeheshti S, Motaghinejad M. "Ramelteon, As a Melatonin Agonist, Is Expected to Be Effective on Covid-19 Induced Organ Damage: The Hypothetic Role of Nf-Κb Signaling Pathway." Advanced Biomedical Research 11, no. 1 (2022): 101-. |
| Harvard | Mehdipoor M et al. (2022) 'Ramelteon, As a Melatonin Agonist, Is Expected to Be Effective on Covid-19 Induced Organ Damage: The Hypothetic Role of Nf-Κb Signaling Pathway', Advanced Biomedical Research, 11(1), pp. 101-. |
| Vancouver | Mehdipoor M, Mirmotahari S, Nouriyani S, Salehirad M, Darbeheshti S, Motaghinejad M. Ramelteon, As a Melatonin Agonist, Is Expected to Be Effective on Covid-19 Induced Organ Damage: The Hypothetic Role of Nf-Κb Signaling Pathway. Advanced Biomedical Research. 2022;11(1):101-. |
| BibTex | @article{ author = {Mehdipoor M and Mirmotahari S and Nouriyani S and Salehirad M and Darbeheshti S and Motaghinejad M}, title = {Ramelteon, As a Melatonin Agonist, Is Expected to Be Effective on Covid-19 Induced Organ Damage: The Hypothetic Role of Nf-Κb Signaling Pathway}, journal = {Advanced Biomedical Research}, volume = {11}, number = {1}, pages = {101-}, year = {2022} } |
| RIS | TY - JOUR AU - Mehdipoor M AU - Mirmotahari S AU - Nouriyani S AU - Salehirad M AU - Darbeheshti S AU - Motaghinejad M TI - Ramelteon, As a Melatonin Agonist, Is Expected to Be Effective on Covid-19 Induced Organ Damage: The Hypothetic Role of Nf-Κb Signaling Pathway JO - Advanced Biomedical Research VL - 11 IS - 1 SP - 101 EP - PY - 2022 ER - |